Sunday, November 13, 2022

Bottomline | The worrisome case of Aurobindo Pharma

Bottomline | The worrisome case of Aurobindo Pharma For equity investors, even a hint of suspect governance is a big red flag. It isn#39;t surprising, therefore, that the Aurobindo Pharma stock came under selling pressure on November 10 after it was reported that its Director, P Sarath Chandra Reddy, had been arrested by the Enforcement Directorate.

from Moneycontrol Business News https://www.moneycontrol.com/news/business/bottomline-|-the-worrisome-caseaurobindo-pharma_16719151.html

No comments:

Post a Comment

LTIMindtree Q4 Preview: Lower pass-through revenue seen impacting growth marginally

A compilation of estimates suggests the company#39;s Q4 FY24 net profit is projected to decline by 2.2 percent quarter on quarter to Rs 1,1...